Laura V Klotz, Swaantje Casjens, Georg Johnen, Dirk Taeger, Alexander Brik, Florian Eichhorn, Laura Förster, Nina Kaiser, Thomas Muley, Christa Stolp, Marc Schneider, Jan Gleichenhagen, Thomas Brüning, Hauke Winter, Martin Eichhorn, Daniel G Weber
BACKGROUND: The role of cytoreductive surgery for epithelioid pleural mesothelioma within a multimodal treatment approach remains controversial. Carefully selected patients benefit from cytoreductive surgery and adjuvant chemotherapy, but there is no established biomarker to predict tumor recurrence or progression during the course of the disease. The aim of this study was to identify potential biomarkers to predict therapeutic response in terms of progression-free survival. METHODS: Between 03/2014 and 08/2022, preoperative blood samples were collected from 76 patients with epithelioid pleural mesothelioma who underwent cytoreductive surgery as part of a multimodal treatment approach...
April 24, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer